FDA Inspection
Enemeez, LLC dba Summit PharmaceuticalsEnemeez, LLC dba Summit Pharmaceuticals – FDA Inspection, Jul 29, 2021
Record Details
This FDA Inspection record concerns Enemeez, LLC dba Summit Pharmaceuticals, with an inspection on July 29, 2021, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- July 29, 2021
- Product Type
- Drugs
View Company Profile
ID · 7e7bbba6-611e-4478-a3de-f582c1b59bd4
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1147428
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
3- 21 CFR 211.166(a)(2)Stability sample storage conditions described
- 21 CFR 211.166(a)(3)Valid stability test methods
- 21 CFR 211.166(a)Written program not followed
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Enemeez, LLC dba Summit Pharmaceuticals
4| Date | Classification | Office | Project area |
|---|---|---|---|
| February 12, 2026 | Not classified | Denver District Office | Drug Quality Assurance |
| August 10, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 6, 2011 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 12, 2010 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Enemeez, LLC dba Summit Pharmaceuticals
- FDA Inspection 1302518 - 2026-02-12
- FDA Inspection 987440 - 2016-08-10
- FDA Inspection 728243 - 2011-06-06
- FDA Inspection 656042 - 2010-03-12
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.